Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

Palbociclib is a small‐molecule, cyclin‐dependent kinase 4 and 6 inhibitor, which prevents phosphorylation of the retinoblastoma (Rb) protein and inhibits cell‐cycle progression from G1 to S phase. We performed this meta‐analysis to estimate the safety and efficacy of palbociclib in cancer patients from clinical trials.

[1]  S. Mani,et al.  Recent advances of highly selective CDK4/6 inhibitors in breast cancer , 2017, Journal of Hematology & Oncology.

[2]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[3]  Ping Chen,et al.  Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.

[4]  M. Kodaira,et al.  Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients , 2016, Cancer science.

[5]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[6]  P. Roberts,et al.  Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression , 2016, Molecular Cancer Therapeutics.

[7]  M. Rosen,et al.  Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors , 2015, Cancer.

[8]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[9]  D. Heitjan,et al.  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.

[10]  T. Traina,et al.  Palbociclib: an evidence-based review of its potential in the treatment of breast cancer , 2014, Breast cancer.

[11]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Rudmann.  On-target and Off-target-based Toxicologic Effects , 2013, Toxicologic pathology.

[13]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[14]  E. Eisenhauer,et al.  Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[16]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[17]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[18]  K. Wilner,et al.  Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.

[19]  Kwok-Kin Wong,et al.  Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. , 2010, The Journal of clinical investigation.

[20]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[21]  M. Aapro,et al.  Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Kaldis,et al.  Cell-specific responses to loss of cyclin-dependent kinases , 2007, Oncogene.

[23]  Wilson Roa,et al.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Barbacid,et al.  Cell cycle kinases in cancer. , 2007, Current opinion in genetics & development.

[25]  J. Baselga,et al.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[27]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[28]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[29]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[30]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[31]  Brian Leyland-Jones,et al.  Breast cancer trial with erythropoietin terminated unexpectedly. , 2003, The Lancet. Oncology.

[32]  G. Lyman.  Balancing the benefits and costs of colony-stimulating factors: a current perspective. , 2003, Seminars in oncology.

[33]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[34]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[35]  M. Somerfield,et al.  clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer , 2010 .

[36]  G. Peters,et al.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.